[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-282931-105":53,"doc-detail-282931-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","patient-speaker-agreement-patient-advisory-board-for-advanced-breast-cancer-compensation-and-confidentiality","Patient Speaker Agreement - Patient Advisory Board for Advanced Breast Cancer - compensation and confidentiality","","Patient Speaker Agreement governs the participation of a named patient representative in a Nordic Patient Advisory Board for Advanced Breast Cancer. The agreement defines the speaking engagement on March 28, 2019, confidentiality expectations, permissible use of patient-provided information by Novartis and affiliates, and limits responsibility for statements made by the patient. It also sets the compensation amount of 3,500 DKK, outlines affiliate control criteria, and specifies return or destruction of confidential materials after the agreement expires.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/patient-speaker-agreement-patient-advisory-board-for-advanced-breast-cancer-compensation-and-confidentiality/282931/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/patient-speaker-agreement-patient-advisory-board-for-advanced-breast-cancer-compensation-and-confidentiality/282931.png","ImageObject",442,249,{"name":88,"@type":89},"McGucket","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-18","2026-09-16",true,{"@type":98,"interactionType":99,"userInteractionCount":47},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What is the patient speaker agreement for?","Question",{"text":108,"@type":109},"It authorizes a patient representative to participate in a Nordic Patient Advisory Board for Advanced Breast Cancer and to share her personal patient perspective during the speaking engagement.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"How will Novartis and its affiliates use the patient’s information?",{"text":113,"@type":109},"Novartis and affiliates may use the information solely for training, educating, and informing directors, officers, employees, and advisors, and they may not use it for other purposes without the patient’s prior written consent.",{"name":115,"@type":106,"acceptedAnswer":116},"What confidentiality obligations apply to the patient?",{"text":117,"@type":109},"The patient must keep Novartis and affiliate information strictly confidential, must not disclose the agreement’s existence or contents to third parties without consent, and must return or destroy confidential documents and data upon request, subject to defined exceptions.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},282931,1790180305,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":47,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":79,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":139,"read_time":73},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DocuSign Envelope ID: 23879B45-7CC8-4D6B-9A09-51F42AE81681  \nPATIENT SPEAKER AGREEMENT  \nThis Agreement (“Agreement”) is entered into as of March 25 2019, between  \nNovartis Healthcare A/S (Reg. No. 20575786), Edvard Thomsens Vej 14, 2300 Köbenhavn S, Denmark (“Novartis”) and Dansk Brystkræft Organisation (DBO) v/ Birgitte Laursen, Brordrupsvej 37, 4621 Gadstrup (“Patient”) .  \nWHEREAS Novartis is committed to patient centricity and in particular to better  \nunderstand patients’ experience with their disease, how patients interact with their physicians, and how Novartis can be responsive to their questions and needs;  \nWHEREAS, for this purpose, Novartis is conducting internal events, for  \nNovartis employees and Novartis management, inviting patients, their caregivers and physicians to share their experience on a disease, how it affects their life, and on related healthcare issues.  \nWHEREAS Patient is willing to take part in one of such events and to provide  \nher personal patient perspective of the patient journey in advanced breast cancer.  \nIn witness thereof, the parties agree as follows:  \n1. Patient agrees to participate in a Nordic Patient Advisory Board for Advanced Breast Cancer. Here she will provide her personal patient perspective of the patient journey in advanced breast cancer (“the Speaking Engagement”) . During the Event, the patient will share her experience around patient information and support, discuss multidisciplinary advisory board and give input to Novartis initiatives in advanced breast cancer. The meeting will take place on March 28 2019 at Clarion Hotel Arlanda/Stockholm, Sweden (“the Event”) .  \n2. Patient confirms that:  \n􀁸 Patient is performing the advisory board service in her own free will and accord.  \n􀁸 Any information that Patient will communicate during the Event will be accurate to the best of Patient’s knowledge, and will reflect Patient’s personal true and honest opinion of her experience and that Novartis shall not be responsible for any statement made by Patient during the Event.  \n3. Novartis and its Affiliates agree to use any such information for the sole purpose of training, educating and informing their respective directors, officers, employees and advisors (including external service providers), and will not use such information for any other purpose without the prior written consent of Patient.  \n4. For the purpose of this Agreement, an entity shall be deemed to be an “Affiliate” of Novartis if it is a company, whether a corporation or other business entity, that is controlling, controlled by or under common control with Novartis. “Control” shall mean  \nDocuSign Envelope ID: 23879B45-7CC8-4D6B-9A09-51F42AE81681  \nthe direct or indirect ownership of more than fifty percent (50%) of the equity interest in such corporation or business entity, or the ability in fact to control the management decisions of such corporation or business entity. Affiliate shall also include the research foundations organized and/or sponsored by Novartis and/or its Affiliates.  \n5. Although the respective directors, officers, employees and business partners of Novartis and its Affiliates who attend the Event have signed confidentiality engagements concerning the information obtained in the course of their relationship or employment with Novartis and its Affiliates, they may disclose and discuss in private circles and outside business and professional context certain elements of the Patient’s testimony during the Event. Patient understands, acknowledges and agrees to such private disclosure and comments on his/her testimony, and under no circumstances, shall Novartis or its Affiliates be held responsible for such private disclosure or comments.  \n6. Any information relating to Novartis or its affiliates or any of its or their businesses, business plans, operations or products acquired by Patient in the course of this Agreement (“Information”) will be kept strictly confidential by Patient and will not be u","cbCaigbFvc4eKgjC","https://ap.wps.com/l/cbCaigbFvc4eKgjC","pdf",319075,"English","# Patient Speaker Agreement\n## Parties and purpose\n## Speaking engagement and responsibilities\n## Information use and affiliate definition\n## Confidentiality and exceptions\n## Compensation and event details","[{\"question\":\"What is the patient speaker agreement for?\",\"answer\":\"It authorizes a patient representative to participate in a Nordic Patient Advisory Board for Advanced Breast Cancer and to share her personal patient perspective during the speaking engagement.\"},{\"question\":\"How will Novartis and its affiliates use the patient’s information?\",\"answer\":\"Novartis and affiliates may use the information solely for training, educating, and informing directors, officers, employees, and advisors, and they may not use it for other purposes without the patient’s prior written consent.\"},{\"question\":\"What confidentiality obligations apply to the patient?\",\"answer\":\"The patient must keep Novartis and affiliate information strictly confidential, must not disclose the agreement’s existence or contents to third parties without consent, and must return or destroy confidential documents and data upon request, subject to defined exceptions.\"}]","Patient Speaker Agreement - Patient Advisory Board for Advanced Breast Cancer - compensation and confidentiality | PDF",1789585344]